Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.

Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...